Icon Plc(ICLR) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 11 at 7:30 PM ET (Korea 9/12 08:30)
Full metrics table
| Index | - | P/E | 307.33 | EPS (ttm) | 0.55 | Insider Own | 1.05% | Shs Outstand | 77.2M | Perf Week | 3.5% |
| Market Cap | 13.06B | Forward P/E | 14.18 | EPS next Y | 12.67% | Insider Trans | -1.27% | Shs Float | 76.3M | Perf Month | 1.28% |
| Enterprise Value | 15.66B | PEG | 5.31 | EPS next Q | 2.68 | Inst Own | 105.3% | Short Float | 3.12% | Perf Quarter | 12.93% |
| Income | 0.04B | P/S | 1.57 | EPS this Y | -15.43% | Inst Trans | 0.56% | Short Ratio | 2.99 | Perf Half Y | 73.74% |
| Sales | 8.29B | P/B | 1.39 | EPS next 5Y | 2.67% | ROA | 0.26% | Short Interest | 2.38M | Perf YTD | -7.08% |
| Book/sh | 121.55 | P/C | 14.07 | EPS past 3/5Y | -22.33% -14.31% | ROE | 0.45% | 52W High | -16.97% ($203.91) | Perf Year | -3.31% |
| Cash/sh | 12.03 | P/FCF | 14.61 | Sales past 3/5Y | 2.15% 24.15% | ROIC | 0.37% | 52W Low | 154.33% ($66.57) | Perf 3Y | -33.72% |
| Dividend Est. | - | EV/EBITDA | 12.56 | EPS Y/Y TTM | -94.18% | Gross Margin | 19.45% | Volatility(W/M) | 3.79% 3.87% | Perf 5Y | -34.58% |
| Dividend TTM | - | EV/Sales | 1.89 | Sales Y/Y TTM | 2.08% | Oper. Margin | 10.14% | ATR (14) | 6.91 | Perf 10Y | 125.33% |
| Dividend Ex-Date | - | Quick Ratio | 0.95 | EPS Q/Q | -63.33% | Profit Margin | 0.51% | RSI (14) | 54.62 | Recom | 2 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.95 | Sales Q/Q | 1.2% | SMA20 | 1.47% ($166.86) | Beta | 1.24 | Target Price | $187.6 |
| Payout | - | Debt/Eq | 0.38 | Earnings | 2026/7/29 | SMA50 | 1.25% ($167.22) | Rel Volume | 2.15 | Prev Close | $165.69 |
| Employees | 40100 | LT Debt/Eq | 0.24 | EPS/Sales Surpr. | 0.57% 2.95% | SMA200 | 14.82% ($147.46) | Avg Volume(3M) | 0.80M | Price | $169.31 |
| IPO | 1998/5/15 | Option/Short | Yes/Yes | Trades | 16042 | Volume | 1,709,990 | Change | 2.18% |
Company
ICLR is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
Headquartered in Ireland, this global contract research organization (CRO) conducts and manages clinical trials of new drugs for pharmaceutical and biotech companies, while providing related data and laboratory services. Its business is underpinned by outsourcing demand for new drug development.
Over the past 1 year, roughly in the middle
17% below its 1-year high.
ICLR has weak earning power
10.14% of revenue is kept as operating profit.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -15.4% this year.
Tap to view numbers
The price looks about right
Trading at 307.3 times earnings.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by -33.7% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 105.3%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
EIRL 0.06%
BAIV 0.05%
TLCI 0.04%
BASV 0.03%
BUSA 0.02%It ranks #4 in the industry
Based on market cap of $13B.
ICLR $13B PER 307.3
TMO $225B PER 32.8
DHR $141B PER 35.5
NTRA $47B PER -
FAQ
What kind of company is ICLR?
ICLR belongs to the Healthcare sector and operates in the Diagnostics & Research industry.
What is the market cap of ICLR?
The market cap of ICLR is approximately $13.1B, ranking 793 within its sector.
What is the P/E ratio of ICLR?
ICLR has a P/E ratio of approximately 307.3x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for ICLR?
ICLR has recorded a 52-week high of $203.91 and a low of $66.57.
